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1. THE ROLE OF PASSENGER LEUKOCYTES IN ALLOGRAFT 
REJECTION 
Early observations by Snell and Steinmuller provided unequivocal evidence that non-
parenchymal cells, resident within the organ play an important role in allograft rejectionl-3. 
However, despite these findings and the subsequent employment of the term "passenger 
leukocytes" to illustrate their migratory capacity4, identity of the donor cells involved in allo-
graft rejection (at that time) was nevertheless enigmatic. These observations nonetheless had 
two unique corollaries for transplantation (Tx). Firstly, that the severity of rejection might be 
mitigated by functionally modulating or depleting donor leukocytes prior to organ tx, and sec-
ondly, that the majority of the transplanted tissue is non-immunogenic and may therefore play 
an infinitesimal role in graft rejection. The realization of the importance of these findings 
prompted the initiation of numerous studies intended to modulate the immune responses by 
manipulating resident non-parenchymal cells prior to transplantations-7• In spite of the novelty 
of these experiments, the success was however, variable. 
1.1. Importance of Dendritic Cells (DC) in Primary Immune Responses 
Whilst the role of passenger leukocytes in initiating allograft rejection was undeni-
able, the identity of the cell(s) which instigated this immune response was however, 
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equivocal. Given their unique capacity to present antigens to naive T cells, it was postu-
lated that perhaps cells of dendritic leukocyte lineage may playa vital role in allosensiti-
zation8• Supporting evidence for the latter argument came from the initial studies by 
Lechler and Batchelor, who demonstrated that allogeneic kidneys were indefinitely ac-
cepted in rodents if they were initially "parked" in an immunosuppressed recipient prior to 
retransplantation into a secondary naive syngeneic animal9• More importantly, the allo-
grafts were acutely rejected if DC obtained from donor-strain animals were infused into 
the secondary recipients indicating that the latter manipulation perhaps, led to the restora-
tion of immunogenicity of the leukocyte-depleted allograft resulting in its prompt rejec-
tion. This and numerous subsequent studies l()"12 have unambiguously established the 
identity of donor DC as the critical passenger leukocytes primarily responsible for allo-
graft rejection, supporting the concept that their elimination prior to Tx may possibly cul-
minate in prolonged graft survival. 
1.2. DC in Transplantation Tolerance 
A diametrical yet entirely compatible role for DC has been proposed by recent stud-
ies in rodents '3• 14 and sub-human primates's. Our laboratory has shown previously that liv-
ers transplanted orthotopically across most mouse strain combinations are spontaneously 
accepted'6. Interestingly, DC isolated from murine livers exhibit phenotype and function 
distinctive of that of immature cells, suggesting perhaps that upon migration from the 
graft into the host, these cells may provide "deviant" signals resulting in induction of do-
nor-specific hyporeactivity rather than allosensitization 13. It is interesting to note that or-
gans other than livers which are promptly rejected following Tx also contain, albeit few, 
resident immature DC". It is therefore entirely conceivable that the inherent tolerogenicity 
uniquely ascribed to murine livers may be contingent on the presence within it an apropos 
quality and quantity of resident leukocytes bearing an immature phenotype. 
1.3. Chimerism and Its Role in Organ Allograft Acceptance 
The ubiquitous detection of the presence of donor cell chimerism in the tissues of 
successful long-term human kidney and liver recipients provided irrevocable evidence for 
the role of microchimerism in Tx tolerance I8. 19• These observations were supported by 
contemporaneous studies in rodents prompting evolvement of a hypothesis that the estab-
lishment of microchimerism by migratory resident leukocytes may playa seminal role in 
the induction of donor-specific tolerance 13. IS. 20.21. Whilst the role of migratory donor cells 
in the induction of donor-specific hyporeactivity was undeniable, the mechanism responsi-
ble for the perpetuation of chimerism and therefore of tolerance, years after organ Tx was 
nevertheless unclear. However, recent studies in rodents22•23 and humans24 , have confirmed 
the presence of pluripotent stem cells in the interstitium of the grafted organ providing ex-
plication for the long-term persistence of donor cell chimerism. 
2. AUGMENTATION OF CHIMERISM IN HUMAN ALLOGRAFT 
RECIPIENTS 
Recognizing the seminal role played by migratory donor leukocytes in allograft ac-
ceptance and the induction of donor-specific tolerance almost four years ago, we em-
barked on a prospective clinical trial to augment the phenomenon in organ recipients by 
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peri operative donor bone marrow (BM) infusion. In addition to verifying the safety of this 
procedure, three long-term goals of this study were to: (i) prevent delayed graft rejection, 
(ii) abrogate or mitigate chronic rejection and (iii) to decrease drug-dependence. Since 
June 1992, lS9 recipients of liver (n=55), kidney (n=36), kidney + pancreas (n=33), kid-
ney + islets (n=7), heart (n=24), lungs (n=IS), small bowel (n=!3) and multi-organ (n=3) 
have received a single peri-operative infusion of 3-{)x 108 BM cells/kg body weight. Addi-
tionally, subsequent to the implementation of a modified protocol in April 1996, ten re-
cipients ofliver (n=5), kidney (n=4), kidney + delayed islets (n= 1) have received multiple 
infusions of! x 108 cells/kg body weight/day for five consecutive days (day 0-4) post-Tx. 
Immunosuppression (IS) was with tacrolimus and steroids; CellCept was added to 
this regimen in 32 study and 15 control patients. BM was isolated from the vertebral bod-
ies (VB) of cadaveric donors by a method described previously 25 and infused intrave-
nously without cryopreservation. The recipients were not conditioned nor was the BM 
modified prior to infusion. The unavailability of consent to retrieve VB from the cadaveric 
donors resulted in accrual of 115 recipients of liver (n=32), kidney (n= 19), kidney + pan-
creas (n=20), kidney + delayed islets (n=2), heart (n=20), lung (n=!O), small bowel (n=7) 
and multiorgan (n= 1) who were followed as contemporaneous controls. Episodes of acute 
rejection were treated with dose adjustments of routine IS, whereas OKT3 was reserved 
for the treatment of steroid-resistant rejection. 
2.1. In Vitro Monitoring 
Using peripheral blood mononuclear cells (PBMC), the immune status of the recipi-
ents was monitored serially by mixed leukocyte reaction (MLR), limiting dilution assay 
and proliferation against recall antigens (ConA and PHA). Using primers specific for 
either HLA-allele or the sex-determining region of the Y (SRY) chromosome (in mal em-
female recipients), the presence of donor DNA was determined periodically in the study 
and control patients. Serial quantitative evaluations of donor cell chimerism in a selected 
cohort of study and control patients were performed using a modified limiting dilution 
PCR (LOA-PCR) assay. The multilineage character of chimerism was also ascertained by 
PCR detection of donor DNA in lineage+ cells sorted from recipients' PBMC. The evi-
dence for the presence of donor DC progenitors and therefore of engraftment was obtained 
by propagation of recipients' PBMC in rhGM-CSF and rhIL-4-enriched cultures. Sub-
sequent to enrichment for lineagenull/MHC class Ir popUlation, the presence of donor DNA 
within the sorted cells was confirmed by PCR analysis. 
2.2. Clinical Outcome 
The ancillary BM infusion was safe and no complications that could be uniquely at-
tributed to this procedure were witnessed in any of the 199 study patients. All but lS/199 
(9%) of BM-augmented recipients are alive compared to 13/115 (II %) of controls, who 
have died during the course of this follow-up (Table I). Additionally, grafts in nine study 
and five control patients have been lost during their successive follow-up (Table I). It is 
noteworthy that no deaths or graft losses in the augmented group were related to BM infu-
sion. No evidence of any inimical complication was witnessed in any of the ten patients 
who have received multiple BM infusion during the course of their follow-up (5-154 
days). All of the surviving patients have adequate graft function. 
Whilst all patients remain IS-dependent, it is nonetheless interesting to note that 
steroid-free existence has been achieved in 61 % study and 40% control patients who are at 
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Table 1. BM-Augmented (study) and non-augmented (control) transplant recipients: 
follow-up and patient graft survival 
Follow-up Patient Survival Graft Survival 
Organs Tx 11 POD (X±SD) (%) (%) 
Liver 
Study 60 610066 53/60 (88%) 51/60 (85%) 
Control 32 798±354 28/32 (88%) 28/32 (88%) 
Kidney 
Study 81 588±311 80/81 (99%) 75/81 (93%) 
Control 41 617±311 38/41 (93%) 37/41 (90%) 
Heart 
Study 24 481±330 21124 (88%) 21124 (88%) 
Control 20 429±226 18/20 (90%) 18/20 (90%) 
Lung 
Study 18 380±269 14/18 (78%) 14/18 (78%) 
Control 10 478±188 8/10 (80%) 8/10 (80%) 
Small Bowel 
Study 13 289±234 10/13 (77%) 9/13 (69%) 
Control 07 302±219 517 (71%) 517 (71 %) 
Multi-organ 
Study 03 508±136 3/3 (100%) 3/3 (100%) 
Control 01 248 III (100%) III (100%) 
least 12 months post-Tx (figure I). Equally significant however, is the observations that a: 
I 
statistically higher number of kidney recipients in the study group (71 %) were weaned off 
steroids as compared to the controls. I 
I 
2.2.1. Incidence of Acute and Chronic Rejection. The tempo, severity and cumula, 
tive incidence of acute cellular rejection was comparable (-60%) in patients in the stud~ 
and control groups. Graft versus host disease was witnessed in only two (l %) BM-augi 
mented recipients (both of liver) which for its resolution required minor dose adjustments 
of routine IS. Whilst histopathological changes pathognomonic of chronic rejection have 
I 
not manifested in any BM-augmented patient, at a comparable duration of follow-up 217 
I (29%) surviving non-augmented lung recipients have however, exhibited evidence for th~ 
development of obliterative bronchiolitis. I 
2.2.2. Multilineage Chimerism and Evidence for Infused Donor Cell Engraftment. ~ 
The incidence of chimerism was much higher (94%) in the BM-augmented patients a~ 
compared to the controls (56%). Additionally, using LDA-PCR, the levels of chimerisri 
were found to be at least 10-100 fold higher in a selected cohort of study patients as com; 
pared to the controls. Furthermore, the presence of donor DNA in sorted lineage+ cell: 
provided unequivocal evidence of the multilineage nature of donor cell chimerism in BM-
augmented patients. It must be emphasized that our ability to identify donor DNA in cui 
tured/sorted (lineage+/class It) cells generated from the PBMC of 4/5 evaluated stud} 
patients who were at least one year post-Tx provide sustenance to our claim that infusei 
marrow may have indeed engrafted. 
2.2.3. In Vitro Immune Modulation. A previously established criteria was used to ac 
cess the extent of donor-specific immune modulation in control and study patients.26 At; 
two-year follow-up, a higher proportion ofBM-augmented liver (50%) and lung (60%) re 
j 
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Figure 1. The incidence of steroid-free existence in 8M-augmented and non-augmented (control) organ recipients 
who are at least 12 months post-Tx. 
cipients exhibited donor-specific hypo or intermediate (DSHI) responses as compared to 
the controls (Figure 2). On the contrary, there was a comparable degree ofimmunomodu-
lation in study and control kidney and heart recipients at a similar duration of follow-up. 
3. CONCLUSION 
Whilst in rodents and large animals, donor-specific tolerance could be achieved in 







o 20 40 60 
DSHI (%) 
Figure 2. The incidence of evolvement of donor-specific hypo or intermediate (DSHI) reactivity determined by 
MLR assay in 8M-augmented and control organ allograft recipients at a two-year follow-up. 
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Given our experience with long-tenn successful organ transplant recipients who are cur-
rently being weaned off IS under a meticulously planned protocol, it is anticipated that 
only a select cohort of patients in this study will ever achieve a drug-free state perhaps 
years if not a decade after Tx. 
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